s potential in the market. A key element is the company’s promising drug, denifanstat, a fatty acid synthase inhibitor, which has shown strong efficacy in Phase 2b trials, particularly among more ...

UBS initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $12 price target As one of the more potent anti-fibrotics UBS has ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development ...

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target ...

GlobalData analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's ...

Key Business Updates BRUKINSA ® (zanubrutinib) is an orally available, small molecule inhibitor of BTK designed to deliver ...

it is known to have inhibitory effects on the respiratory and circulatory systems and is associated with a high incidence of injection site pain. Ciprofol, a novel, nonbarbiturate, general intravenous ...